13G Filing: James E. Flynn and Biocryst Pharmaceuticals Inc (BCRX)
You can access the original SEC filing by clicking here.
Biocryst Pharmaceuticals Inc (BCRX)
Market is closed
News
- First
- << Previous
- 41 - 50
- Next >>
BioCryst Pharmaceuticals, Inc. (BCRX): A Discount Entry?
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has caught our attention in the biotech space as being a company that has had a bit of a strange start to the week.
What Smart Money Thinks about BioCryst Pharmaceuticals, Inc. (BCRX)?
Investing in hedge funds can bring large profits, but it’s not for everybody, since hedge funds are available only for high-net-worth individuals.
Biocryst Pharmaceuticals Inc (BCRX): Baker Bros. Advisors Unloads Nearly 4 Million Shares
Julian Baker and Felix Baker's Baker Bros. Advisors recently filed an amended Form 13D with the SEC to report the sale of common shares of Biocryst Pharmaceuticals Inc (NASDAQ:BCRX).
Most Popular Healthcare Stocks Under $5
Most securities that cost less than a dinner at a fast-food restaurant are considered to be too risky, with most intra-day traders or other investors usually avoiding these low-priced stocks.
Biotech-Focused VHCP Management's Bullish Moves and New Picks
Biotech stocks pop and drop on the smallest whims and whispers, which makes the biotechnology sector one of the most rewarding and volatile sectors out there.
Venrock Healthcare Capital Partners Discloses 7.1% Stake in Biocryst Pharmaceuticals Inc (BCRX)
Anders Hove and Bong Koh's VHCP Management owns a new position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), as a new filing with the US Securities and Exchange Commision showed.
D. E. Shaw & Co Raises Exposure to Biocryst Pharmaceuticals Inc (BCRX)
D. E. Shaw & Co, founded by billionaire David E. Shaw, has reported its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) via a 13G filing with the US Securities and Exchange Commission.
- First
- << Previous
- 41 - 50
- Next >>
Billionaire Hedge Funds
